Apart from their insulinotropic effects, their GI effects provide therapeutic possibilities for a wide scale of GI diseases, including functional dyspepsia, dumping syndrome, IBS, IBD, short bowel syndrome, NAFLD/NASH and cholestatic disorders
In the United States, the prevalence ranges from 10% to 15%, with a higher incidence observed in women
Snack: Greek yogurt with blueberries, an ideal semaglutide snack rich in protein and antioxidants
By stimulating the GLP-1 receptor, Semaglutide slows digestion, reduces appetite, and can significantly lower blood sugar levels
they do not affect folate metabolism, renal clearance, or hepatic enzyme pathways in a clinically meaningful way